title: Cancer-killing CAR therapies gain speed.
abstract: In recent clinical trials, engineered CAR T cells have yielded response rates as high as 90% in patients with leukemia. Now, scientists are working to get this therapy to market and possibly expand its use into solid tumors.
authors.forename: Melissa
authors.initials: M
authors.lastname: Weber
mesh_terms: D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000235:genetics* / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000235:genetics* / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism*
chemical_list: D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins